NEW YORK — Exact Sciences said this week that it has awarded a total of $1.5 million to 28 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program, which provides grants to community organizations, health foundations, public health organizations, and advocacy groups working to increase access to colorectal cancer screening and awareness.
Since its launch in 2022, FOCUS has awarded more than $4.5 million to over 75 organizations throughout the United States.
Opko Health announced this week that its board of directors has authorized the repurchase of up to $100 million in shares of the company's stock, or about 10 percent of the firm's 697 million shares outstanding at the current stock price. The firm will use its cash and cash equivalents and future cash flows to repurchase shares through the open market, private transactions, and accelerated repurchase transactions, including purchases through Rule 10b5-1 trading plans.
Specialty cancer diagnostics firm Precipio reported this week second quarter unaudited revenues of $4.4 million, up sequentially from $3.4 million in Q1. The New Haven, Connecticut-based firm also said that it was making progress toward profitability. Its pathology division surpassed the breakeven point starting in June, and its products division is preparing to launch in Q3 and Q4 a portfolio of assays that company officials anticipate will generate sufficient revenues to cross the breakeven point.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.